List of Excipients in Branded Drug VIZAMYL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
GE Healthcare Inc (Medi-Physics Inc dba GE Healthcare)	VIZAMYL	flutemetamol f-18	17156-067	ALCOHOL	2028-09-16
GE Healthcare Inc (Medi-Physics Inc dba GE Healthcare)	VIZAMYL	flutemetamol f-18	17156-067	POLYSORBATE 80	2028-09-16
GE Healthcare Inc (Medi-Physics Inc dba GE Healthcare)	VIZAMYL	flutemetamol f-18	17156-067	SODIUM CHLORIDE	2028-09-16

VIZAMYL Excipient Strategy and Commercial Opportunities

Last updated: August 5, 2026

VIZAMYL is a fluorine-18 radiopharmaceutical containing flutemetamol F 18 for positron emission tomography imaging of beta-amyloid neuritic plaque density in adults evaluated for Alzheimer’s disease and other cognitive decline. Its commercial opportunity is concentrated in sterile excipient supply, radiopharmaceutical manufacturing, container systems, quality control, and formulation-support services rather than in conventional oral-drug excipient innovation.

The formulation uses a small excipient platform, which limits direct substitution opportunities but increases the importance of impurity control, radiochemical stability, sterility, endotoxin control, and rapid batch release. VIZAMYL is marketed by GE HealthCare and was approved by the FDA in 2013 under NDA 203137. [1]

What excipients are used in VIZAMYL?

VIZAMYL is supplied as a sterile intravenous injection containing flutemetamol F 18 in an aqueous formulation. The U.S. prescribing information identifies ethanol, polysorbate 80, sodium chloride, and phosphate-buffer components among the formulation ingredients. The exact radioactive concentration varies with the calibration time and manufacturing batch. [1]

Formulation element	Function in VIZAMYL	Commercial relevance
Water for injection	Primary vehicle	Sterile pharmaceutical-water supply and validated filling
Ethanol	Solvent and radiochemical formulation aid	High-purity, low-residue, GMP-grade supply
Polysorbate 80	Surfactant and solubilization aid	Control of peroxides, hydrolysis products, particulates, and container interaction
Sodium chloride	Tonicity adjustment	Low-risk commodity excipient, but still subject to injectable-grade controls
Phosphate buffer components	pH control	Buffer capacity, ionic strength, compatibility, and radiolysis control
Flutemetamol F 18	PET imaging agent	Short half-life creates time-critical manufacturing and distribution requirements

Fluorine-18 has a physical half-life of approximately 110 minutes. The short half-life affects every excipient decision because the product must be manufactured, tested, released, transported, and administered within a narrow operating window. [2]

Why is polysorbate 80 important in VIZAMYL?

Polysorbate 80 is the most technically sensitive conventional excipient in the formulation. Its degradation can generate peroxides, aldehydes, free fatty acids, and particulates. Those impurities can affect radiochemical purity, flutemetamol solubilization, filter performance, and injectable-product quality.

A commercial polysorbate 80 strategy should control:

• Peroxide value and hydroperoxide burden
• Acid value and fatty-acid profile
• Water content
• Residual solvents
• Trace metals
• Subvisible particles
• Lot-to-lot molecular-weight distribution
• Compatibility with the product-contact container and sterilizing filter

The strongest supply opportunity is not simply selling polysorbate 80. It is supplying a characterized, low-peroxide, injectable-grade material with a documented control strategy and reliable lot release.

What role does ethanol play in the formulation?

Ethanol functions as a solvent and can support the solubility and formulation of flutemetamol. Its concentration must remain within a validated range because changes can affect drug partitioning, radiochemical stability, container compatibility, extractables, and patient tolerability.

Potential suppliers can compete through:

• Sterile or low-bioburden GMP ethanol
• Tight control of water content
• Low aldehyde and ketone levels
• Validated single-use packaging
• Fast regional delivery to radiopharmacy sites
• Certificates of analysis suited to FDA-regulated injectable manufacturing

Ethanol is unlikely to create meaningful product differentiation by itself. The commercial value lies in supply reliability and documentation.

How does the short half-life change VIZAMYL excipient strategy?

The short half-life makes VIZAMYL different from conventional injectables. Stability is measured over hours rather than years, while the product still requires validated sterile manufacturing and quality controls.

An excipient strategy must address four linked risks:

1. Radiolysis of the active ingredient or formulation components.
2. Time-dependent changes in pH, particulates, and radiochemical purity.
3. Manufacturing delays caused by failed or slow quality-control testing.
4. Product loss when distribution or administration occurs outside the validated window.

Excipient suppliers can therefore create value through manufacturing support rather than new chemical entities. High-value services include rapid release testing, prequalified backup supply, regional inventory, and formulation-specific impurity monitoring.

What formulation opportunities exist for VIZAMYL?

The most credible opportunities fall into five categories.

Low-peroxide surfactant platforms

A supplier could offer a polysorbate 80 grade designed for radiopharmaceutical use. The product would need a narrow impurity profile, low oxidative burden, validated filtration behavior, and strong extractables data.

The commercial model could include:

• Dedicated lots for radiopharmaceutical manufacturers
• Retest and stability programs
• Regional inventory near PET manufacturing centers
• Technical agreements covering impurity excursions
• Co-development of alternative surfactant systems

Any replacement of polysorbate 80 would require comparative data on solubility, radiochemical purity, sterility, endotoxin, particulates, filterability, and short-term stability.

Buffer optimization

Phosphate concentration and pH can influence radiolysis, solubility, osmolality, and container compatibility. A lower-capacity buffer or a different buffer system could potentially improve robustness, but it would also create a formulation-change burden.

A buffer supplier could compete through prequalified sterile concentrates, ready-to-use solutions, or single-use mixing systems. The commercial benefit would be lower preparation time and reduced compounding variability.

Single-use formulation components

Radiopharmaceutical manufacturers may benefit from presterilized containers, sterile filters, tubing assemblies, and formulation bags designed for short production cycles. These products can reduce cleaning validation and shorten batch preparation.

The strongest opportunity is a validated system that integrates:

• Low-binding fluid paths
• Low extractables
• Radiation-compatible materials
• Sterilizing-grade filtration
• Barcoded lot traceability
• Rapid connection and disconnection
• Compatibility with automated synthesis or dispensing equipment

Container and closure systems

The container system must protect the product from contamination and minimize adsorption or leachable exposure. Potential materials include radiation-compatible glass and polymeric components, depending on the validated presentation.

Commercial development should focus on:

• Low extractables and leachables
• Low adsorption of flutemetamol
• Shielding compatibility
• Accurate withdrawal of small volumes
• Septum integrity
• Compatibility with automated dose dispensers

Container improvements may be more commercially defensible than commodity excipient substitution because they can be tied to manufacturing efficiency and radiation-safety workflows.

Automated dispensing and dose-management systems

Because VIZAMYL is radioactive and time-sensitive, automated dose measurement and dispensing can reduce operator exposure, dose variability, and waste. A supplier that combines formulation containers with calibrated dispensing hardware could capture more value than an excipient-only supplier.

What patent protection covers VIZAMYL excipients and formulations?

The public FDA prescribing information establishes the approved formulation but does not, by itself, establish the scope of any formulation patent claims. Excipient suppliers should separate four types of intellectual property:

IP category	Potential subject matter	Commercial impact
Active-agent patents	Flutemetamol, labeled precursors, or synthetic intermediates	May restrict active-ingredient manufacture
Formulation patents	Solvent, surfactant, buffer, concentration, or stability combinations	May restrict substitution or reformulation
Manufacturing patents	Radiolabeling, purification, sterilization, or dispensing processes	May create process barriers
Device and packaging patents	Shielded vials, cassettes, dose systems, or containers	May affect equipment and packaging entry

A supplier should not assume that an excipient listed in the label is free of patent risk. Patent protection may attach to the combination of excipient, concentration, pH, manufacturing sequence, or container system rather than to the excipient itself.

The commercially relevant question is whether a proposed formulation change reads on an active claim and whether the change would require a new FDA filing. A supplier can often avoid direct product patent exposure by selling a well-characterized excipient as a raw material without marketing a competing VIZAMYL product. That approach does not eliminate process, supply, or regulatory risks.

When does VIZAMYL lose exclusivity?

VIZAMYL’s FDA approval date was October 25, 2013. The three-year period of marketing exclusivity associated with new clinical investigations would have expired in 2016, assuming no separate regulatory extension. [1, 3]

Patent expiration cannot be determined from the prescribing information alone. A current freedom-to-operate analysis must review issued U.S. patents, terminal disclaimers, patent-term adjustment, patent-term extension, Orange Book listings, and litigation records.

Does VIZAMYL have biosimilar risk?

No. VIZAMYL is a small-molecule radiopharmaceutical, not a biologic. Biosimilar competition under the Public Health Service Act does not apply. A competing product would more likely use an abbreviated new drug application, a 505(b)(2) application, or a full NDA, depending on the proposed active ingredient, labeling, formulation, manufacturing process, and reliance on FDA findings. [4]

What generic-entry risks exist for VIZAMYL?

Generic-entry risk is constrained by more than patent status. A competing manufacturer must address:

• Production of flutemetamol F 18 or an equivalent active ingredient
• Radiolabeling and purification
• Sterile manufacturing
• Short shelf life
• Site-specific distribution
• PET-center scheduling
• Radiochemical and chemical impurities
• Labeling and image-interpretation requirements
• FDA comparability expectations

An ANDA applicant would seek to demonstrate sameness in active ingredient, dosage form, route, strength, quality, and labeling. A formulation or manufacturing difference may push the applicant toward a 505(b)(2) pathway.

What FDA regulatory issues affect excipient changes?

Excipient changes can trigger different regulatory consequences depending on their scale.

Change	Likely regulatory concern
New supplier of the same compendial excipient	Supplier qualification, comparability, and updated CMC documentation
Different grade of polysorbate 80	Impurity profile, stability, particulates, and compatibility
New buffer system	pH, osmolality, radiochemical purity, tolerability, and stability
Different ethanol concentration	Solubility, radiolysis, container compatibility, and clinical bridging
New container closure	Extractables, leachables, adsorption, sterility, and integrity
New manufacturing site	Process validation, aseptic controls, and release testing
New formulation	Potential prior-approval supplement or new regulatory application

The key regulatory principle is that the excipient is part of the drug product’s quality system. A substitution is not commercially complete when the material passes a compendial test. The manufacturer must show that the change does not alter critical quality attributes.

Which companies can compete in the VIZAMYL excipient supply chain?

The competitive landscape includes four supplier groups:

1. Large pharmaceutical excipient manufacturers supplying polysorbates, ethanol, buffers, and injectable-grade materials.
2. Specialized radiopharmaceutical contract development and manufacturing organizations.
3. Sterile filtration, single-use systems, and container-closure suppliers.
4. Automated radiopharmacy equipment and dose-management companies.

GE HealthCare remains the reference commercial manufacturer for VIZAMYL. [1] Competing suppliers are more likely to win business through qualified second-source status, regional manufacturing, technical documentation, and integrated production systems than through an unqualified lower price.

How strong is the commercial opportunity?

The opportunity is strongest where an excipient or component reduces manufacturing failure, radioactive waste, operator exposure, or batch-release time.

Opportunity	Revenue potential	Entry barrier	Strategic assessment
Commodity sodium chloride	Low	Low	Limited differentiation
GMP ethanol	Low to moderate	Moderate	Attractive where regional supply is constrained
Injectable polysorbate 80	Moderate	High	Best excipient opportunity because impurity control matters
Buffer concentrates	Moderate	Moderate	Useful for standardized radiopharmacy production
Sterile filters and fluid paths	Moderate to high	High	Strong recurring consumables model
Container-closure systems	Moderate to high	High	Defensible through validation and compatibility data
Automated dispensing systems	High	High	Higher capital value and workflow integration
Formulation redesign	High	Very high	Requires substantial regulatory and comparability work

What litigation and settlement issues affect VIZAMYL?

No biosimilar litigation framework applies to VIZAMYL. Generic or follow-on challenges would typically focus on patent validity, infringement, regulatory pathway, and manufacturing equivalence.

A settlement involving a generic applicant could establish an authorized launch date or other commercial restrictions, but no settlement terms should be inferred without reviewing the relevant court docket, FDA submissions, and agreement. Excipient suppliers should monitor litigation because a settlement can change the timing of demand for alternative formulations and manufacturing capacity.

How does VIZAMYL compare with other amyloid PET tracers?

Product	Active agent	Radionuclide	Main formulation opportunity
VIZAMYL	Flutemetamol F 18	Fluorine-18	Surfactant control, sterile fluid paths, automated dispensing
Amyvid	Florbetapir F 18	Fluorine-18	Similar short-half-life and sterile radiopharmaceutical requirements
Neuraceq	Florbetaben F 18	Fluorine-18	Similar supply-chain and radiochemical-stability constraints
Tauvid	Flortaucipir F 18	Fluorine-18	Specialized PET formulation and manufacturing controls

The main competitive variable is not excipient complexity. It is reliable production, dose availability, image quality, PET-site logistics, and reimbursement. Excipients become commercially important when they improve batch success rates or extend the practical operating window.

Key Takeaways

• VIZAMYL is a short-half-life fluorine-18 injectable radiopharmaceutical, not a biologic.
• Its key formulation ingredients include ethanol, polysorbate 80, sodium chloride, phosphate-buffer components, and water for injection.
• Low-peroxide polysorbate 80 is the most technically attractive excipient opportunity.
• Sterile fluid paths, container systems, filters, and automated dispensing equipment may offer greater commercial value than commodity excipients.
• VIZAMYL’s three-year FDA exclusivity period expired in 2016.
• Biosimilar competition does not apply. Generic or 505(b)(2) competition remains technically and operationally difficult.
• Excipient substitution can require comparability, stability, container-closure, and regulatory approval work.
• The strongest commercial strategy is to sell validated materials and manufacturing systems that reduce radioactive waste, batch failure, release time, and operator exposure.

FAQs

Can polysorbate 80 be removed from VIZAMYL?

Possibly, but removal would require reformulation studies addressing solubility, radiochemical purity, particulates, sterility, adsorption, and short-term stability. It would not be a routine excipient change.

Is VIZAMYL supplied as a lyophilized excipient kit?

No. VIZAMYL is supplied as a ready-to-use sterile injection rather than as a conventional lyophilized product requiring bedside reconstitution. [1]

Can a company sell an alternative VIZAMYL formulation using the same active ingredient?

A company may develop a competing flutemetamol F 18 product, but the regulatory pathway would depend on formulation sameness, manufacturing differences, labeling, patent position, and the ability to demonstrate quality and clinical comparability.

Which excipient has the highest technical risk in VIZAMYL?

Polysorbate 80 has the highest excipient-specific technical risk because oxidative degradation can produce reactive impurities and particulates that affect injectable-product quality.

What is the best licensing target in the VIZAMYL supply chain?

The most attractive licensing targets are validated low-peroxide surfactant systems, radiation-compatible container assemblies, automated dispensing platforms, and manufacturing processes that improve radiochemical yield or reduce radioactive waste.

References

1. U.S. Food and Drug Administration. (2024). Vizamyl (flutemetamol F 18 injection) prescribing information. GE Healthcare.

2. International Atomic Energy Agency. (2014). Cyclotron produced radionuclides: Guidance on targetry and processing. IAEA.

3. U.S. Food and Drug Administration. (2024). New drug application exclusivity. In Approved drug products with therapeutic equivalence evaluations.

4. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2). FDA.

5. European Medicines Agency. (2014). Vizamyl: EPAR product information. European Medicines Agency.